{"contentid": 488336, "importid": NaN, "name": "Hemogenyx goes it alone with AML-targeting antibody", "introduction": "London-listed blood disease specialist Hemogenyx Pharmaceuticals (LSE: HEMO) has provided an update on the development of its lead product candidate, a CDX bispecific antibody.", "content": "<p>London-listed blood disease specialist Hemogenyx Pharmaceuticals (LSE: HEMO) has provided an update on the development of its lead product candidate, a CDX bispecific antibody.</p>\n<p>While the firm had been in negotiations with an undisclosed global pharmaceutical company regarding further development, that firm has now declined to take the project further, Hemogenyx said on Wednesday.</p>\n<p>The announcement caused shares in the company to fall almost 40% in pre-market trading.</p>\n<p>Hemogenyx, which is developing the antibody for the treatment of acute myeloid leukemia (AML) and other potential applications, will now exercise its own option to license the intellectual property of its partner on an exclusive, worldwide basis.</p>\n<p>The firm will thus take the program forward independently, while working actively with its partner to &ldquo;determine the exact terms of the licence,&rdquo; as well as the firm&rsquo;s &ldquo;continued involvement in the progression of CDX toward clinical trials.&rdquo;</p>\n<p>Chief executive Vladislav Sandler said: \"We are pleased with the progress of our negotiations with 'GlobalCo' and their continued interest in working with Hemogenyx Pharmaceuticals. We look forward to advancing our CDX antibody to clinical trials.\"</p>\n<p>At the same time, the company is progressing its CAR-T cell candidate, HEMO-CAR-T, having initiated engagement with contract manufacturing organizations (CMO) for product development and manufacturing to support Phase I clinical trials.</p>", "date": "2021-04-14 11:01:00", "meta_title": NaN, "meta_keywords": "Hemogenyx, antibody, development, Pharmaceuticals, candidate, product, AML-targeting, specialist, disease, blood, London-listed, firm, HEMO, update, lead", "meta_description": "London-listed blood disease specialist Hemogenyx Pharmaceuticals (LSE: HEMO) has provided an update on the development of its lead product candidate, a CDX bisp", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-14 11:01:22", "updated": "2021-04-14 11:09:51", "access": NaN, "url": "https://www.thepharmaletter.com/article/hemogenyx-goes-it-alone-with-aml-targeting-antibody", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "hemogenyx_big.png", "image2id": "hemogenyx_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Deals, Drug Trial, Licensing, One to Watch Companies, Research", "geography_tag": "UK", "company_tag": "HemoGenyx Pharmaceuticals", "drug_tag": "HEMO-CAR-T", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-14 11:01:00"}